MIAMI BEACH, Fla., March 9, 2018 /PRNewswire/ -- Longeveron Co-Founder Joshua Hare, M.D. addressed international experts and attendees at the International Conference on Frailty and Sarcopenia Research (ICFSR), held March 1- 3 in Miami Beach. Dr. Hare, who spoke at a special symposium on aging, provided the latest updates on how the company's mesenchymal stem cell therapy continues to generate promise for treating Aging Frailty, Alzheimer's Disease and other conditions associated with aging.
"Aging Frailty affects and seriously impairs the quality of life for up to 3.6 million Americans older than age 65 in the U.S., so there is a great unmet need for effective treatments," said Dr. Hare, who is also Longeveron's Chief Scientific Officer.
The symposium, "Regenerative Medicine to Treat Chronic, Debilitating Conditions Associated with Aging," sponsored by Longeveron, was held on March 2 at the Miami Beach Resort and Spa. Symposium expert topics and speakers included:
- Treating Aging Frailty with Donor Mesenchymal Stem Cells: A Phase 2b Multicenter Clinical Trial, presented by Joshua M. Hare, M.D.
- Frailty and Immunosenescence: Impact on Influenza Vaccination in Older Adults and Strategies to Intervene, presented by Sean X. Leng, M.D., Ph.D., Associate Professor of Medicine, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine in Baltimore.
- Cellular Therapy to Treat Alzheimer's Disease, presented by Bruno Vellas, M.D., Professor of Internal Medicine and Geriatrics, Chair, Toulouse Gérontopôle University Hospital in Toulouse, France.
The symposium was designed as an interactive forum for discussing the therapeutic potential for regenerative medicine to treat chronic, debilitating conditions associated with aging.
Dr. Hare also delivered a keynote presentation on March 1, The Rationale, Biological and Clinical Impact of Stem Cell Therapy for Aging Frailty.
About the 2018 International Conference on Frailty and Sarcopenia Research
With the aging of the world's population, maintaining functional independence during old age has emerged as one of the most important clinical and public health priorities worldwide. Addressing these concerns, an international group of industry and academic scientists investigating frailty and age-related muscle loss (sarcopenia) met in Miami Beach, Florida, March 1 through 3, 2018 to explore the underlying mechanisms, possible interventions, and the development of tools to enable clinical trials for these disabling disorders of aging.
The ICFSR 2018, convened by the International Academy of Nutrition and Aging, was co-sponsored by the Toulouse Gérontopôle, Toulouse, France; the U.S. Department of Veterans Affairs' Geriatric Research Education and Clinical Center (GRECC), Miami; and Tufts University, Boston, Massachusetts. Congress chairmen included Professors Roger Fielding (Boston), Marco Pahor (Gainesville, FL), and Matteo Cesari, Yves Rolland, and Bruno Vellas (Toulouse, France).
Longeveron was a Silver Sponsor of the ICFSR 2018 conference.
About Longeveron
Longeveron LLC is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's Disease, Aging Frailty, and the Metabolic Syndrome. The company gratefully acknowledges the generous support of the National Institutes of Health and the Alzheimer's Association. Longeveron is also conducting a Phase 1 trial with the University of Maryland and Johns Hopkins University to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, and gratefully acknowledges the support and collaboration from the Maryland Stem Cell Research Fund.
To learn more, visit Longeveron.com.
View original content:http://www.prnewswire.com/news-releases/longeveron-shares-latest-advances-to-treat-aging-frailty-at-the-international-conference-on-frailty-and-sarcopenia-research-300611505.html
SOURCE Longeveron LLC
Share this article